Biogen Inc. buy tamam
Summary
This prediction ended on 21.07.16 with a price of €236.69. The price of Biogen Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.64%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Biogen Inc. | 7.014% | 7.014% | -29.290% | -11.509% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
Comments by tamam for this prediction
In the thread Biogen Inc. diskutieren
Biogen: Ready For A Bounce?
tamam stimmt am 09.08.2015 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 355.62€ zu.
A director bought over $3 million in new shares last week. It was the first purchase by an insider in at least a year and a half. It also is one of the top five purchases by an insider for the week ending 07/30. More importantly, Biogen has a promising pipeline.The first drug in that pipeline that should hit the market is Zinbryta which is developed in a partnership with Abb Vie, and that is pending approval in both Europe and the United States. Zinbryta is a once-monthly injection for treating relapsing-remitting multiple sclerosis. This will probably cannibalize sales of its product Avonex, which requires a weekly injection but is a better potential solution for MS patients.Staying in the MS space, the company is also developing a compound called Anti-LINGO-1 which is in phase II trials. If successful, this drug could be a multi-billion blockbuster as it could allow MS patients to help regrow myelin, which could start to restore nerve communication.The possible "gorilla" in Biogen's pipeline is Aducanumab, a potential treatment for Alzheimer's that affects a large population, and is growing rapidly due to the aging of the western world. The company is currently enrolling patients for an upcoming Phase III trial. Obviously, any positive trial results would be a huge catalyst for the stock as this drug would have mega-blockbuster potential.